Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations
Authors:
- 4 June 2010
- journal article
- editorial
- Published by Springer Nature in Diabetologia
- Vol. 53 (9) , 1823-1826
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trialsDiabetologia, 2010
- Combined randomised controlled trial experience of malignancies in studies using insulin glargineDiabetologia, 2009
- Metformin, Cancer, Alphabet Soup, and the Role of Epidemiology in Etiologic ResearchDiabetes Care, 2009
- Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology GroupDiabetologia, 2009
- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort studyDiabetologia, 2009
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Comparison of evidence on harms of medical interventions in randomized and nonrandomized studiesCanadian Medical Association Journal, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Metformin and reduced risk of cancer in diabetic patientsBMJ, 2005
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998